Literature DB >> 18370846

Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.

Alan H B Wu1, Ping Wang, Andrew Smith, Christine Haller, Katherine Drake, Mark Linder, Roland Valdes.   

Abstract

OBJECTIVES: Polymorphism in the genes for cytochrome (CYP)2C9 and the vitamin K epoxide reductase complex subunit 1 (VKORC1) affect the pharmacokinetics and pharmacodynamics of warfarin. We developed and validated a warfarin-dosing algorithm for a multi-ethnic population that predicts the best dose for stable anticoagulation, and compared its performance against other regression equations.
METHODS: We determined the allele and haplotype frequencies of genes for CYP2C9 and VKORC1 on 167 Caucasian, African-American, Asian and Hispanic patients on warfarin. On a subset where complete data were available (n=92), we developed a dosing equation that predicts the actual dose needed to maintain target anticoagulation using demographic variables and genotypes. This regression was validated against an independent group of subjects. We also applied our data to five other published warfarin-dosing equations.
RESULTS: The allele frequency for CYP2C9*2 and *3 and the A allele for VKORC1 3673 was similar to previously published reports. For Caucasians and Asians, VKORC1 SNPs were in Hardy-Weinberg linkage equilibrium. Some VKORC1 SNPs among the African-American population and one SNP among Hispanics were not in equilibrium. The linear regression of predicted versus actual warfarin dose produced r-values of 0.71 for the training set and 0.67 for the validation set. The regression coefficient improved (to r=0.78 and 0.75, respectively) when rare genotypes were eliminated or when the 7566 VKORC1 genotype was added to the model. All of the regression models tested produced a similar degree of correlation. The exclusion of rare genotypes that are more associated with certain ethnicities improved the model.
CONCLUSION: Minor improvements in algorithms can be observed with the inclusion of ethnicity and more CYP2C9 and VKORC1 SNPs as variables. Major improvements will likely require the identification of new gene associations with warfarin dosing.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18370846     DOI: 10.2217/14622416.9.2.169

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  59 in total

1.  Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.

Authors:  Stuart A Scott; Rame Khasawneh; Inga Peter; Ruth Kornreich; Robert J Desnick
Journal:  Pharmacogenomics       Date:  2010-06       Impact factor: 2.533

2.  Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy.

Authors:  Chun Li; Ute I Schwarz; Marylyn D Ritchie; Dan M Roden; C Michael Stein; Daniel Kurnik
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

3.  Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders.

Authors:  Julia Kirchheiner; Cristina Rodriguez-Antona
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

4.  Improved accuracy of anticoagulant dose prediction using a pharmacogenetic and artificial neural network-based method.

Authors:  Hussain A Isma'eel; George E Sakr; Robert H Habib; Mohamad Musbah Almedawar; Nathalie K Zgheib; Imad H Elhajj
Journal:  Eur J Clin Pharmacol       Date:  2013-12-03       Impact factor: 2.953

5.  Multiplex pyrosequencing method to determine CYP2C9*3, VKORC1*2, and CYP4F2*3 polymorphisms simultaneously: its application to a Korean population and comparisons with other ethnic groups.

Authors:  Kyoung-Ah Kim; Wan-Geun Song; Hae-Mi Lee; Hyun-Jin Joo; Ji-Young Park
Journal:  Mol Biol Rep       Date:  2014-07-29       Impact factor: 2.316

6.  Evaluation of a reverse-hybridization StripAssay for the detection of genetic polymorphisms leading to acenocoumarol sensitivity.

Authors:  Argyri Gialeraki; Christos Markatos; Elisabeth Grouzi; Efrosyni Merkouri; Anthi Travlou; Marianna Politou
Journal:  Mol Biol Rep       Date:  2009-06-28       Impact factor: 2.316

7.  Use of novel oral anticoagulants in patients with heart failure.

Authors:  Eduard Shantsila; Gregory Y H Lip
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-02

Review 8.  The future of warfarin pharmacogenetics in under-represented minority groups.

Authors:  Larisa H Cavallari; Minoli A Perera
Journal:  Future Cardiol       Date:  2012-07

9.  VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study.

Authors:  Fatima Donia Mili; Tenecia Allen; Paula Weinstein Wadell; W Craig Hooper; Christine De Staercke; Christopher J Bean; Cathy Lally; Harland Austin; Nanette K Wenger
Journal:  Future Cardiol       Date:  2017-12-08

10.  Thrombotic genetic risk factors and warfarin pharmacogenetic variants in São Miguel's healthy population (Azores).

Authors:  Claudia C Branco; Tânia Pereirinha; Rita Cabral; Paula R Pacheco; Luisa Mota-Vieira
Journal:  Thromb J       Date:  2009-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.